Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Inhibitor”

70 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 70 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 480
Large-scale testing (Phase 3)Study completedNCT03361865
What this trial is testing

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

Who this might be right for
UC (Urothelial Cancer)
Incyte Corporation 93
Testing effectiveness (Phase 2)Study completedNCT03797326
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerOvarian Cancer+5 more
Merck Sharp & Dohme LLC 611
Not applicableUnknownNCT04922541
What this trial is testing

Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Who this might be right for
Plaque, AtheroscleroticProgrammed Cell Death Protein 1 Inhibitor
Second Affiliated Hospital, School of Medicine, Zhejiang University 50
Early research (Phase 1)Study completedNCT04393506
What this trial is testing

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Who this might be right for
Oral CancerVEGFR2 InhibitorProgrammed Cell Death 1 Inhibitor+1 more
Shanghai Jiao Tong University School of Medicine 21
Early research (Phase 1)Study completedNCT04881045
What this trial is testing

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Who this might be right for
Non-Small Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckOvarian Cancer
Pfizer 29
Early research (Phase 1)Looking for participantsNCT05142189
What this trial is testing

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
BioNTech SE 320
Testing effectiveness (Phase 2)Study completedNCT03322566
What this trial is testing

Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Who this might be right for
Lung Cancer
Incyte Corporation 233
Testing effectiveness (Phase 2)Active Not RecruitingNCT04626479
What this trial is testing

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 400
Early research (Phase 1)Ended earlyNCT04155580
What this trial is testing

ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Astex Pharmaceuticals, Inc. 68
Testing effectiveness (Phase 2)Study completedNCT04669899
What this trial is testing

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Who this might be right for
Cancer
Jounce Therapeutics, Inc. 190
Large-scale testing (Phase 3)Active Not RecruitingNCT06790966
What this trial is testing

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Recurrent Head and Neck CancerMetastatic Head and Neck CancerHPV Positive Oropharyngeal Squamous Cell Carcinoma+2 more
PDS Biotechnology Corp. 252
Not applicableUnknownNCT04253080
What this trial is testing

Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors

Who this might be right for
Cutaneous Melanoma
Assistance Publique - Hôpitaux de Paris 170
Testing effectiveness (Phase 2)Active Not RecruitingNCT05565378
What this trial is testing

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 351
Testing effectiveness (Phase 2)Study completedNCT03322540
What this trial is testing

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Who this might be right for
Lung Cancer
Incyte Corporation 154
Testing effectiveness (Phase 2)Study completedNCT04305041
What this trial is testing

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 100
Large-scale testing (Phase 3)Study completedNCT03713593
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 794
Testing effectiveness (Phase 2)Study completedNCT04995419
What this trial is testing

Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy

Who this might be right for
Metastatic Urothelial Cancer
Astellas Pharma China, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT00882869
What this trial is testing

XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Who this might be right for
Advanced Hepatocellular Carcinoma
Aegera Therapeutics 75
Testing effectiveness (Phase 2)Ended earlyNCT03116529
What this trial is testing

Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

Who this might be right for
Soft Tissue Sarcoma
University of Maryland, Baltimore 22
Load More Results